X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ATI 7505 (naronapride) is a potential best-in-class oral, locally acting pan-GI prokinetic, that acts as 5-HT4 receptor agonist and D2 receptor antagonist. It is being evaluated for the treatment of Gastroparesis.
Lead Product(s): Naronapride
Therapeutic Area: Gastroenterology Product Name: ATI 7505
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Falk Pharma GmbH
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 27, 2024
Details:
ATI-7505 (naronapride) is an orally bioavailable, small organic molecule. It was designed to be a potent and selective serotonin 5-HT4 receptor agonist and D2 antagonist. Its IND application has been cleared by USFDA for the treatment of PPI-Non-Responsive Symptomatic GERD.
Lead Product(s): Naronapride
Therapeutic Area: Gastroenterology Product Name: ATI-7505
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 24, 2024
Details:
ATI-7505 (naronapride) is a 5-HT4 agonist, small molecule drug candidate, which is currently being evaluated for the treatment of proton-pump inhibitor non-responsive symptomatic gastroesophageal reflux disease.
Lead Product(s): Naronapride
Therapeutic Area: Gastroenterology Product Name: ATI-7505
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
ATI-7505 (naronapride) is a late-development stage, pan-GI prokinetic. It is a highly selective 5HT-4 agonist and D2 antagonist, is being developed for GI motility in cystic fibrosis.
Lead Product(s): Naronapride
Therapeutic Area: Gastroenterology Product Name: Naronapride
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2023
Details:
Naronapride possess both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties. It is currently being investigaetd for chronic idiopathic constipation (CIC) and gastro-esophageal reflux disease (GERD).
Lead Product(s): Naronapride
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 10, 2023
Details:
The collaboration with Dr. Falk Pharma will serve as a catalyst to Renexxion advancing Naronapride, a drug candidate which possesses combination of both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties to patients with GI motility disorders.
Lead Product(s): Naronapride
Therapeutic Area: Gastroenterology Product Name: ATI-7505
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Falk Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 05, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
